Real-world use of once-weekly semaglutide in patients with type 2 diabetes: results from the SURE Switzerland multicentre, prospective, observational study.

Details

Serval ID
serval:BIB_A13642524285
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Real-world use of once-weekly semaglutide in patients with type 2 diabetes: results from the SURE Switzerland multicentre, prospective, observational study.
Journal
Diabetes research and clinical practice
Author(s)
Rudofsky G., Catarig A.M., Favre L., Grau K., Häfliger S., Thomann R., Schultes B.
ISSN
1872-8227 (Electronic)
ISSN-L
0168-8227
Publication state
Published
Issued date
01/07/2021
Peer-reviewed
Oui
Pages
108931
Language
english
Notes
Publication types: Journal Article
Publication Status: aheadofprint
Abstract
SURE Switzerland (NCT03631186) investigated real-world once-weekly (OW) semaglutide use in adults with type 2 diabetes (T2D).
This multicentre, prospective, observational study enrolled adults with T2D with ≥1 documented HbA <sub>1c</sub> value ≤12 weeks before semaglutide initiation. Primary endpoint was change in HbA <sub>1c</sub> from baseline to end of study (EOS; ∼30 weeks). Secondary endpoints included changes in body weight (BW) and waist circumference (WC), and the proportion of patients achieving HbA <sub>1c</sub> <8.0%, <7.5% and <7.0% at EOS. Semaglutide dose at EOS was a prespecified exploratory endpoint.
Overall, 214 patients initiated semaglutide (baseline HbA <sub>1c</sub> 7.8% [62 mmol/mol], BW 99.9 kg and WC 117.4 cm); 187 attended the EOS visit. At EOS, 175 (81.8%) were still receiving semaglutide (mean [SD] dose 0.78 [0.29] mg); in those patients, mean HbA <sub>1c</sub> reduced by -0.8 [95% CI -1.01;-0.68] %-points (-9 [-11;-7] mmol/mol), BW by -5.0 kg [-5.73;-4.24] and WC by -4.8 cm [-5.75;-3.79] (all p<0.0001). At EOS, 85.9%, 76.5% and 55.9% patients achieved, respectively, HbA <sub>1c</sub> <8.0%, <7.5% and <7.0%. No new safety signals were identified.
Patients with T2D in Switzerland initiating OW semaglutide experienced clinically relevant glycaemic control and BW improvements in a real-world setting, supporting semaglutide use in routine clinical practice.
Keywords
Glucagon-like peptide-1 receptor agonist, Glucose control, Real-world evidence, SURE study, Semaglutide, Type 2 diabetes
Pubmed
Open Access
Yes
Create date
12/07/2021 9:47
Last modification date
15/07/2021 6:37
Usage data